The following are today’s latest 159 analyst ratings tracked from muliple analysts for American listed and traded stocks:
Accenture PLC (ACN): JPMorgan Chase lowered the target price from $302 to $290 while maintaining an Overweight rating, reflecting slightly more conservative revenue expectations.
Accenture PLC (ACN): Deutsche Bank lowered the target price from $260 to $235 with a Hold rating, reflecting caution on near-term growth.
Accenture PLC (ACN): TD Cowen lowered the target price from $313 to $295 with a Buy rating, reflecting moderate slowdown in consulting demand.
Accenture PLC (ACN): Robert W. Baird lowered the target price from $350 to $330 with an Outperform rating, reflecting conservative outlook despite long-term potential.
Accenture PLC (ACN): Guggenheim lowered the target price from $305 to $285 with a Buy rating, reflecting tempered revenue growth expectations.
Accenture PLC (ACN): BMO Capital Markets set the target price at $270, reflecting updated market assumptions.
Accenture PLC (ACN): Royal Bank of Canada lowered the target price from $372 to $285 with an Outperform rating, reflecting valuation concerns amid slower growth.
Accenture PLC (ACN): Cowen reiterated a Buy rating, reflecting confidence in long-term consulting opportunities.
Accenture PLC (ACN): Goldman Sachs lowered the target price from $370 to $330 with a Buy rating, reflecting cautious near-term outlook.
Accenture PLC (ACN): HSBC lowered the target price from $240 to $215, reflecting slower near-term revenue growth.
American Airlines Group (AAL): UBS Group raised the target price from $12 to $13 while maintaining a Neutral rating, reflecting modest improvement in operational outlook.
Americas Gold and Silver Corporation (USAS): Desjardins initiated coverage with a Buy rating at a stock price of $3.52.
Allarity Therapeutics (ALLR): Ascendiant Capital Markets raised the target price from $9.00 to $9.25 with a Buy rating, reflecting positive clinical developments.
Allstate (ALL): Roth Capital set a Buy rating with a $230 target, reflecting steady insurance growth and favorable market conditions.
Allegiant Travel (ALGT): UBS Group raised the target price from $52 to $65 with a Neutral rating, reflecting improved travel demand and operational outlook.
Alkermes plc (ALKS): Royal Bank of Canada upgraded the rating from Sector Perform to Outperform and raised the target price from $42 to $44, reflecting stronger pipeline and revenue growth expectations.
Amgen Inc. (AMGN): Bank of America raised the target price from $261 to $272 but maintained an Underperform rating, reflecting valuation concerns despite pipeline progress.
Apellis Pharmaceuticals (APLS): Goldman Sachs downgraded the rating from Neutral to Sell and cut the target price from $26 to $18, reflecting disappointing product performance or market headwinds.
AppLovin Corporation (APP): UBS Group raised the target price from $540 to $810 with a Buy rating, reflecting strong user growth and advertising monetization.
AppLovin Corporation (APP): Piper Sandler raised the target price from $500 to $740 with an Overweight rating, reflecting improved digital ad revenue trends.
Atmos Energy (ATO): Mizuho raised the target price from $164 to $170 with a Neutral rating, reflecting stable utility operations.
Atome Plc (ATOM): Canaccord Genuity Group raised the target price from GBX 130 to GBX 140 with a Speculative Buy rating, reflecting growth potential in e-commerce.
Babcock International Group (BAB): Berenberg Bank raised the target price from GBX 1,360 to GBX 1,440 with a Buy rating, reflecting stronger contract wins and margin improvement.
Braskem S.A. (BAK): UBS Group downgraded the rating from Buy to Neutral and lowered the target price from $5.10 to $3.80, reflecting weaker commodity market expectations.
BlackBerry Limited (BB): Canaccord Genuity Group reiterated a Hold rating at $4.60, reflecting steady software revenue but limited upside.
BlackBerry Limited (BB): Royal Bank of Canada set the target price at $4.50, reflecting cautious outlook on turnaround.
BlackBerry Limited (BB): Robert W. Baird raised the target price from $5.00 to $5.50 with a Neutral rating, reflecting optimism on software and security solutions.
Brookfield Business Partners L.P. (BBU): Scotiabank raised the target price from $36 to $39 with a Sector Outperform rating, reflecting portfolio growth and infrastructure opportunities.
Brookfield Business Partners L.P. (BBU): Scotiabank reiterated an Outperform rating, reflecting stable long-term fundamentals.
Brookfield Renewable Partners L.P. (BEP): Mizuho raised the target price from $26 to $27 with a Neutral rating, reflecting renewable energy growth and steady cash flows.
Brookfield Infrastructure Partners LP (BIP): National Bankshares set an Outperform rating with a $35 target, reflecting strong infrastructure investment potential.
Birkenstock Holding PLC (BIRK): Telsey Advisory Group reiterated an Outperform rating at $70, reflecting strong brand growth and retail demand.
Cidara Therapeutics (CDTX): HC Wainwright raised the target price from $74 to $110 with a Buy rating, reflecting promising clinical developments.
CG Oncology (CGON): JPMorgan Chase raised the target price from $41 to $47 with an Overweight rating, reflecting favorable clinical progress.
Ciena Corporation (CIEN): Rosenblatt Securities upgraded the rating from Neutral to Buy and raised the target price from $127.50 to $175, reflecting stronger demand for networking solutions.
Cipher Mining (CIFR): JPMorgan Chase raised the target price from $6 to $12 with a Neutral rating, reflecting improved cryptocurrency mining outlook.
Cleanspark (CLSK): JPMorgan Chase reiterated the rating with the target price lowered from $15 to $14, reflecting moderation in clean energy solutions growth.
Costco Wholesale (COST): JPMorgan Chase lowered the target price from $1,160 to $1,050 with an Overweight rating, reflecting slower near-term retail sales.
Costco Wholesale (COST): Goldman Sachs raised the target price from $1,333 to $1,418 with a Buy rating, reflecting stronger long-term fundamentals.
Costco Wholesale (COST): DA Davidson reiterated a Neutral rating at $1,000, reflecting steady performance.
Costco Wholesale (COST): Truist Financial lowered the target price from $1,042 to $1,033 with a Hold rating, reflecting moderate near-term pressures.
Costco Wholesale (COST): Evercore ISI lowered the target price from $1,060 to $1,025 with an Outperform rating, reflecting cautious sales outlook..
Costco Wholesale (COST): Oppenheimer reiterated an Outperform rating at $1,130, reflecting confidence in Costco’s long-term growth potential and stable membership-driven revenue.
Costco Wholesale (COST): Morgan Stanley lowered the target price from $1,225 to $1,130 with an Overweight rating, reflecting moderation in near-term retail sales and cautious outlook on margin expansion.
Costco Wholesale (COST): Roth Capital set the target price at $907 with a Neutral rating, reflecting concerns about near-term cost pressures and slower sales growth.
Costco Wholesale (COST): Sanford C. Bernstein raised the target price slightly from $1,137 to $1,140 with an Outperform rating, reflecting steady fundamentals and continued confidence in Costco’s membership-based model.
CRH (CRH): Bank of America initiated coverage with a Buy rating at $128, reflecting growth in construction materials.
Crinetics Pharmaceuticals (CRNX): Robert W. Baird raised the target price from $58 to $62 with an Outperform rating, reflecting positive clinical data.
Crinetics Pharmaceuticals (CRNX): Goldman Sachs raised the target price from $35 to $40 with a Neutral rating, reflecting cautious optimism.
Crinetics Pharmaceuticals (CRNX): JMP Securities raised the target price from $86 to $143 with a Market Outperform rating, reflecting strong pipeline potential.
CSX (CSX): Robert W. Baird lowered the target price from $44 to $39 with an Outperform rating, reflecting near-term transportation demand concerns.
Cintas (CTAS): Citigroup raised the target price from $172 to $176 with a Sell rating, reflecting valuation concerns despite solid operations.
Camping World (CWH): Citigroup raised the target price from $21 to $22 with a Buy rating, reflecting improving retail conditions.
Dave Inc. (DAVE): Citizens JMP and JMP Securities raised the target price from $280 to $300 with a Market Outperform rating, reflecting growth in fintech operations.
DeFi Technologies (DEFT): HC Wainwright reiterated a Buy rating at $5.50, reflecting continued exposure to decentralized finance growth.
DENTSPLY SIRONA Inc. (XRAY): Needham & Company LLC reiterated a Hold rating, reflecting steady dental equipment demand with limited near-term catalysts.
Dollar General (DG): Gordon Haskett lowered the target price from $130 to $115, reflecting moderate retail headwinds.
DICK’S Sporting Goods (DKS): BNP Paribas initiated coverage with an Underperform rating at $177, reflecting cautious retail outlook.
Duke Energy (DUK): Jefferies downgraded from Buy to Hold and lowered the target price from $141 to $134, reflecting slower utility growth.
DexCom (DXCM): Robert W. Baird lowered the target price from $112 to $90 with an Outperform rating, reflecting moderation in diabetes device demand.
Dycom Industries (DY): Wells Fargo raised the target price from $295 to $305 with an Overweight rating, reflecting stronger infrastructure services demand.
Electronic Arts (EA): Citigroup reiterated a Neutral rating, reflecting steady gaming performance.
Enlivex Therapeutics (ENLV): D. Boral Capital reiterated a Buy rating at $13, reflecting ongoing positive clinical pipeline developments.
EnQuest (ENQ): Canaccord Genuity raised the target price from GBX 19 to GBX 20 with a Buy rating, reflecting improving oil production outlook.
EOG Resources (EOG): Scotiabank reiterated the rating with Sector Perform, reflecting stable energy production and commodity exposure.
Freeport-McMoRan (FCX): CICC Research lowered the target price from $51.60 to $42.30 with an Outperform rating, reflecting weaker copper and gold price assumptions.
First Horizon (FHN): DA Davidson initiated a Neutral rating at $24, reflecting steady banking fundamentals.
Fox Corporation (FOXA): Bank of America raised the target price from $65 to $70 with a Buy rating, reflecting strong media revenue outlook.
Fox Corporation (FOXA): Guggenheim raised the target price from $62 to $68 with a Buy rating, reflecting optimism on advertising and streaming growth.
First Merchants (FRME): Raymond James downgraded the rating from Outperform to Market Perform, reflecting moderate banking headwinds.
First Merchants (FRME): Keefe, Bruyette & Woods raised the target price from $49 to $50 with an Outperform rating, reflecting stable financial performance.
H.B. Fuller (FUL): Citigroup lowered the target price from $70 to $62 with a Neutral rating, reflecting softer near-term industrial demand.
Guardant Health (GH): Canaccord Genuity raised the target price from $65 to $75 with a Buy rating, reflecting strong diagnostic test adoption.
Glenveagh Properties (GLV): Deutsche Bank upgraded to a Buy rating, reflecting residential property growth potential.
Genco Shipping & Trading (GNK): SEB Equity Research set the target price at $23, reflecting steady shipping market expectations.
GeoVax Labs (GOVX): D. Boral Capital reiterated a Buy rating at $9, reflecting ongoing vaccine development.
Guardian Pharmacy Services (GRDN): Truist Financial raised the target price from $28 to $30 with a Buy rating, reflecting expansion in pharmacy operations.
Heritage Financial (HFWA): DA Davidson reiterated a Buy rating at $28, reflecting steady banking performance.
Halma (HLMA): Shore Capital reiterated a Hold rating at GBX 3,352, reflecting stable industrial technology demand.
Intercontinental Hotels Group (IHG): JPMorgan Chase upgraded the rating from Neutral to Overweight, reflecting recovery in hospitality demand.
Immuneering (IMRX): Chardan Capital raised the target price from $13 to $20 with a Buy rating, reflecting promising therapeutics pipeline.
Immunic (IMUX): HC Wainwright reiterated a Buy rating at $10, reflecting steady clinical development.
Ionis Pharmaceuticals (IONS): Goldman Sachs upgraded the rating from Sell to Neutral and raised the target price from $45 to $65, reflecting stronger pipeline visibility.
IREN Limited (IREN): JPMorgan Chase reiterated the rating, downgraded from Neutral to Underweight, and raised the target price from $16 to $24, reflecting operational and market risks.
Jabil (JBL): Barclays raised the target price from $223 to $267 with an Overweight rating, reflecting electronics manufacturing demand.
JD.com (JD): Arete Research initiated coverage at $41, reflecting e-commerce potential.
JD.com (JD): Arete upgraded the rating from Sell to Buy, reflecting stronger online retail performance.
Johnson Service Group (JSG): Berenberg Bank reiterated a Buy rating at GBX 195, reflecting steady business services demand.
Kenvue Inc. (KVUE): Redburn Partners set the target price at $22.00, reflecting initial confidence in near-term stability and product pipeline potential.
Kenvue Inc. (KVUE): Rothschild & Co Redburn upgraded the rating from Neutral to Buy and adjusted the target price from $22.00 to $22.50, reflecting stronger growth outlook and improved market positioning.
Klaviyo, Inc. (KVYO): Stephens lowered the target price from $45.00 to $43.00 and maintained an Overweight rating, reflecting tempered near-term growth expectations in marketing automation demand.
Klaviyo, Inc. (KVYO): Piper Sandler reiterated an Overweight rating and lowered the target price from $55.00 to $50.00, reflecting more cautious guidance on customer acquisition trends.
Klaviyo, Inc. (KVYO): Robert W. Baird lowered the target price from $44.00 to $39.00 and maintained an Outperform rating, reflecting moderation in revenue growth expectations while remaining confident in long-term market share gains.
Klaviyo, Inc. (KVYO): Needham & Company LLC reiterated a Buy rating with a target price of $45.00, reflecting confidence in sustainable growth potential and client retention.
Kratos Defense & Security Solutions, Inc. (KTOS): Robert W. Baird raised the target price from $70.00 to $87.00 and maintained an Outperform rating, reflecting optimism in defense contracts and government spending growth.
Levi Strauss & Co. (LEVI): Barclays raised the target price from $24.00 to $26.00 and maintained an Overweight rating, reflecting stronger retail demand and positive brand momentum.
LightPath Technologies, Inc. (LPTH): Lake Street Capital raised the target price from $4.00 to $7.50 and maintained a Buy rating, reflecting improved product adoption and expected revenue growth.
LightPath Technologies, Inc. (LPTH): HC Wainwright raised the target price from $7.00 to $8.00 and maintained a Buy rating, reflecting increasing market traction and expanding client base.
Live Nation Entertainment, Inc. (LYV): Benchmark raised the target price from $180.00 to $190.00 and maintained a Buy rating, reflecting growing concert attendance and post-pandemic recovery in live events.
Macerich Company (MAC): Bank of America upgraded the rating from Neutral to Buy and raised the target price from $19.00 to $23.00, reflecting improving retail property fundamentals and leasing activity.
Marathon Digital Holdings, Inc. (MARA): JPMorgan Chase & Co. lowered the target price from $22.00 to $20.00 and maintained an Overweight rating, reflecting short-term volatility in cryptocurrency prices while maintaining long-term operational confidence.
Marathon Petroleum Corporation (MPC): UBS Group raised the target price from $203.00 to $220.00 and maintained a Buy rating, reflecting strong refining margins and improved operational efficiency.
McKesson Corporation (MCK): JPMorgan Chase & Co. raised the target price from $821.00 to $853.00 and maintained an Overweight rating, reflecting steady pharmaceutical distribution growth and resilient healthcare demand.
Magnite, Inc. (MGNI): Rosenblatt Securities reiterated a Buy rating with a target price of $39.00, reflecting confidence in digital advertising demand and programmatic platform growth.
Methanex Corporation (MEOH): National Bank Financial initiated coverage with an Outperform rating and set a target price of $47.00, reflecting optimism on methanol market demand and margin stability.
Mirion Technologies, Inc. (MIR): JPMorgan Chase & Co. initiated coverage with an Overweight rating and set a target price of $28.00, reflecting confidence in nuclear measurement solutions growth and contract wins.
Microsoft Corporation (MSFT): Morgan Stanley raised the target price from $582.00 to $625.00 and maintained an Overweight rating, reflecting strong cloud adoption, AI integration, and stable enterprise revenue growth.
Mondelez International, Inc. (MDLZ): Evercore ISI lowered the target price from $73.00 to $72.00 and maintained an Outperform rating, reflecting slower near-term revenue growth while maintaining confidence in long-term brand strength.
Morgan Stanley (MS): Citigroup raised the target price from $130.00 to $155.00 and maintained a Neutral rating, reflecting improved capital market activity and earnings stability.
ONE Gas, Inc. (OGS): Mizuho upgraded the rating from Neutral to Outperform and raised the target price from $77.00 to $86.00, reflecting stronger utility performance and stable earnings outlook.
Okta, Inc. (OKTA): Royal Bank of Canada reiterated an Outperform rating with a target price of $115.00, reflecting confidence in cybersecurity demand and enterprise adoption.
Okta, Inc. (OKTA): BTIG Research reiterated a Buy rating with a target price of $142.00, reflecting long-term growth in identity management solutions.
Okta, Inc. (OKTA): DA Davidson reiterated a Buy rating with a target price of $140.00, reflecting continued enterprise demand and subscription revenue stability.
Oracle Corporation (ORCL): UBS Group set the target price at $364.00, reflecting confidence in cloud business growth and strong enterprise software demand.
Oracle Corporation (ORCL): Sanford C. Bernstein raised the target price from $363.00 to $364.00 and maintained an Outperform rating, reflecting robust cloud adoption and strong earnings visibility.
Organogenesis (ORGO): BTIG Research reiterated a Buy rating with a target price of $7.00, reflecting continued demand for regenerative medicine products.
OSI Systems, Inc. (OSIS): Bank of America raised the target price from $250.00 to $265.00 and maintained a Buy rating, reflecting solid performance in security and healthcare solutions.
Palo Alto Networks, Inc. (PANW): UBS Group set the target price at $245.00, reflecting strong cybersecurity demand and enterprise adoption trends.
Palo Alto Networks, Inc. (PANW): Tigress Financial initiated coverage with a Buy rating and set a target price of $245.00, reflecting strong long-term growth potential in network security solutions.
Palvella Therapeutics, Inc. (PVLA): Chardan Capital raised the target price from $60.00 to $73.00 and maintained a Buy rating, reflecting promising clinical development milestones.
Paycom Software, Inc. (PAYC): Guggenheim initiated coverage with a Buy rating and set a target price of $270.00, reflecting strong HR technology adoption and consistent revenue growth.
Paychex, Inc. (PAYX): Wolfe Research lowered the target price from $145.00 to $140.00 and maintained an Underperform rating, reflecting slowing small-business payroll trends and cautious near-term guidance.
Poolbeg Pharma PLC (POLB): Shore Capital reiterated the rating at GBX 3.89, reflecting continued clinical development with moderate near-term catalysts.
Pure Storage, Inc. (PSTG): Wells Fargo & Company raised the target price from $80.00 to $100.00 and maintained an Overweight rating, reflecting increasing demand for flash storage and cloud solutions.
Pure Storage, Inc. (PSTG): Evercore ISI raised the target price from $85.00 to $90.00 and maintained an Outperform rating, reflecting stronger enterprise adoption and revenue visibility.
Pure Storage, Inc. (PSTG): Guggenheim raised the target price from $93.00 to $105.00 and maintained a Buy rating, reflecting optimism about long-term growth in storage solutions.
Pure Storage, Inc. (PSTG): Needham & Company LLC raised the target price from $85.00 to $100.00 and maintained a Buy rating, reflecting confidence in recurring revenue and expanding enterprise adoption.
Quince Therapeutics, Inc. (QNCX): D. Boral Capital reiterated a Buy rating with a target price of $4.00, reflecting optimism on ongoing clinical programs.
Rapt Therapeutics (RAPT): Leerink Partners upgraded the rating from Market Perform to Outperform and raised the target price from $16.00 to $37.00, reflecting positive clinical trial results and pipeline potential.
Ralph Lauren Corporation (RL): JPMorgan Chase & Co. raised the target price from $423.00 to $430.00 and maintained an Overweight rating, reflecting strong brand positioning and recovery in retail sales.
Redwood Trust, Inc. (RWT): BTIG Research reiterated a Buy rating with a target price of $8.50, reflecting confidence in mortgage REIT performance and yield potential.
Rollins, Inc. (ROL): JPMorgan Chase & Co. initiated coverage with an Overweight rating and set a target price of $70.00, reflecting steady pest control service growth and recurring revenue.
Seplat Energy Plc (SEPL): Canaccord Genuity Group raised the target price from GBX 465 to GBX 550 and maintained a Buy rating, reflecting positive upstream production outlook and commodity price support.
TD SYNNEX Corporation (SNX): Barclays raised the target price from $140.00 to $164.00 and maintained an Equal Weight rating, reflecting balanced risk/reward in IT distribution growth.
TD SYNNEX Corporation (SNX): Morgan Stanley raised the target price from $173.00 to $181.00 and maintained an Overweight rating, reflecting confidence in IT services demand and distribution efficiency.
TD SYNNEX Corporation (SNX): Bank of America raised the target price from $170.00 to $180.00 and maintained a Buy rating, reflecting strong growth in technology distribution and enterprise services.
TD SYNNEX Corporation (SNX): Royal Bank of Canada raised the target price from $165.00 to $180.00 and maintained an Outperform rating, reflecting improving technology product demand and distribution leverage.
Spyre Therapeutics, Inc. (SYRE): Deutsche Bank Aktiengesellschaft initiated coverage with a Buy rating and set a target price of $43.00, reflecting optimism on clinical trial progress and oncology pipeline potential.
Tempus AI, Inc. (TEM): Guggenheim raised the target price from $80.00 to $95.00 and maintained a Buy rating, reflecting growth in AI-driven healthcare data analytics adoption.
Thor Industries, Inc. (THO): BMO Capital Markets reiterated an Outperform rating, reflecting continued demand in recreational vehicle markets.
Thor Industries, Inc. (THO): Citigroup raised the target price from $112.00 to $122.00 and maintained a Neutral rating, reflecting moderate near-term market challenges despite steady fundamentals.
Tesla, Inc. (TSLA): Wedbush raised the target price from $500.00 to $600.00 and maintained an Outperform rating, reflecting growth in EV deliveries and energy storage adoption.
Tesla, Inc. (TSLA): Royal Bank of Canada reiterated a Buy rating, reflecting strong EV market position and production expansion.
Tesla, Inc. (TSLA): Deutsche Bank Aktiengesellschaft raised the target price from $345.00 to $435.00 and maintained a Buy rating, reflecting solid demand for EVs and confidence in cost efficiencies.
Tetra Technologies, Inc. (TTI): Northland Securities set the target price at $7.00, reflecting stable operations in oilfield services and moderate near-term growth.
Twilio Inc. (TWLO): Rosenblatt Securities reiterated a Buy rating with a target price of $140.00, reflecting continued growth in cloud communication APIs.
United Airlines Holdings Inc (UAL): UBS Group raised the target price from $114.00 to $131.00 and maintained a Buy rating, reflecting recovery in travel demand and operational efficiency improvements.
United States Antimony Co. (UAMY): HC Wainwright raised the target price from $4.50 to $8.50 and maintained a Buy rating, reflecting improving commodity pricing and production expansion.
United Therapeutics Corporation (UTHR): Royal Bank of Canada initiated coverage with an Outperform rating and set a target price of $569.00, reflecting growth in rare disease treatments and pipeline potential.
Ultrapar Participacoes S.A. (UGP): Goldman Sachs raised the target price from $4.00 to $4.50 and maintained a Buy rating, reflecting stable downstream energy operations and margin improvement.
Uranium Energy Corp. (UEC): Goldman Sachs raised the target price from $13.00 to $17.00 and maintained a Buy rating, reflecting optimism on uranium pricing and production potential.
Valmont Industries, Inc. (VMI): JPMorgan Chase & Co. initiated coverage with an Overweight rating and set a target price of $480.00, reflecting strong infrastructure demand and project backlog visibility.
Vertex, Inc. (VERX): Stephens initiated coverage with an Overweight rating and set a target price of $30.00, reflecting confidence in dermatology drug growth and pipeline potential.
Vail Resorts, Inc. (MTN): Morgan Stanley reiterated a Cautious rating, reflecting near-term tourism uncertainty and winter season variability.
Vail Resorts, Inc. (MTN): Morgan Stanley raised the target price from $146.00 to $155.00 and issued an Equal Weight rating, reflecting solid recovery in visitor numbers while maintaining cautious outlook on discretionary spending.
Warner Bros. Discovery, Inc. (WBD): KeyCorp reiterated an Overweight rating and changed it to Sector Weight, reflecting mixed media market trends and integration risks.
Western Copper & Gold Corp (WRN): HC Wainwright raised the target price from $4.00 to $4.25 and maintained a Buy rating, reflecting positive exploration results and copper market potential.
WhiteFiber, Inc. (WYFI): Macquarie raised the target price from $28.00 to $32.00 and maintained an Outperform rating, reflecting confidence in fiber optic expansion and revenue growth.
Wix.com Ltd. (WIX): Piper Sandler raised the target price from $206.00 to $210.00 and maintained an Overweight rating, reflecting ongoing growth in website building and SaaS subscription revenues.
